Drugs Containing Excipient (Inactive Ingredient) CORN OIL

« Back to Dashboard

Branded drugs containing CORN OIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	SANDIMMUNE	cyclosporine	0078-0240	CORN OIL
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	CORN OIL
Rebel Distributors Corp	DELSYM	dextromethorphan polistirex	21695-517	CORN OIL
Prasco Laboratories	AMPHETAMINE EXTENDED-RELEASE ORAL SUSPENSION	amphetamine	66993-360	CORN OIL

Generic drugs containing CORN OIL excipient

Company	Ingredient	NDC	Excipient
Novartis Pharmaceuticals Corporation	cyclosporine	0078-0240	CORN OIL
Novartis Pharmaceuticals Corporation	cyclosporine	0078-0246	CORN OIL
Hikma Pharmaceuticals USA Inc	ciprofloxacin	0143-9927	CORN OIL
Mylan Pharmaceuticals Inc	isotretinoin	0378-6611	CORN OIL

Corn Oil Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Regulation, and Competitive Outlook

Last updated: October 10, 2026

Corn oil is an established lipid excipient used mainly as a vehicle, solvent, and formulation component in soft gelatin capsules, oral liquids, lipid-based drug-delivery systems, and some parenteral products. Its pharmaceutical market is stable but low-growth relative to specialty excipients such as medium-chain triglycerides, lipid nanoparticles, and functional polymers.

The financial outlook is tied to commodity corn-oil prices, pharmaceutical-grade processing capacity, demand for softgels and lipid formulations, and substitution by more oxidation-stable or performance-oriented oils. Corn oil has no standalone pharmaceutical exclusivity period, Orange Book listing, or Paragraph IV litigation profile. Commercial protection generally arises from quality systems, supply agreements, formulation know-how, and manufacturing controls rather than composition-of-matter patents.

What is corn oil used for in pharmaceutical formulations?

Corn oil is a fixed vegetable oil derived from the germ of maize. In pharmaceutical applications, it functions primarily as an oily vehicle and solvent.

Pharmaceutical function	Typical application
Vehicle	Oral liquids, softgel fills, lipid-based formulations
Solvent	Lipophilic active pharmaceutical ingredients
Carrier oil	Vitamins, nutraceuticals, and poorly water-soluble compounds
Emollient	Topical and dermatological products
Lipid phase	Emulsions and self-emulsifying drug-delivery systems
Processing aid	Capsule-fill and formulation manufacturing

Pharmaceutical-grade corn oil is usually refined, bleached, and deodorized. Manufacturers control peroxide value, acid value, moisture, impurities, residual solvents, microbial quality, and oxidation products. The required specification depends on the route of administration and dosage form.

Corn oil is particularly compatible with soft gelatin capsules because it provides a liquid lipid phase with broad availability and established processing experience. It is less differentiated than synthetic or semisynthetic excipients designed to improve bioavailability, release control, or nanoparticle formation.

What is the regulatory status of corn oil as a pharmaceutical excipient?

Corn oil is an established excipient rather than a new chemical entity. Regulatory treatment depends on the formulation, route, grade, supplier qualification, and compendial status.

United States

The FDA evaluates corn oil as part of the finished drug application. The excipient does not receive an independent marketing approval. Sponsors must establish that the selected grade is suitable for its intended use and that the finished product meets applicable safety, quality, identity, strength, and purity requirements.

The FDA Inactive Ingredient Database is a key reference for prior use of excipients in approved drug products. Listed use does not create a general approval for every route or concentration. It provides historical context for safety and regulatory precedent. Sponsors remain responsible for product-specific justification and quality control. [1]

Corn oil may appear in approved oral, softgel, or other dosage forms, but the exact acceptable use depends on the product and route. Parenteral use carries materially higher requirements for endotoxins, particulate matter, sterility, oxidation, and container compatibility.

European Union

In the European Union, excipient acceptability is assessed within the marketing authorization dossier. The European Pharmacopoeia and national pharmacopoeial standards may apply depending on the material and product. The European Medicines Agency has also emphasized excipient risk assessment, including route-specific safety and quality considerations. [2]

Compendial and quality status

Pharmaceutical buyers commonly require compliance with one or more of the following:

• USP-NF or equivalent compendial requirements
• European Pharmacopoeia requirements where applicable
• Good Manufacturing Practice controls
• Certificate of analysis for each lot
• Traceability from agricultural source to finished excipient
• Oxidative stability data
• Allergen and genetically modified organism documentation
• Residual pesticide and contaminant testing

Corn oil is not automatically interchangeable across suppliers. Two materials may meet a broad identity specification but differ in fatty-acid profile, antioxidant system, peroxide development, and performance during storage.

How large is the pharmaceutical corn oil market?

No major public company reports pharmaceutical corn oil revenue as a standalone business line. Market research reports generally aggregate corn oil into broader categories such as vegetable oils, pharmaceutical excipients, lipid excipients, nutraceutical ingredients, or softgel materials.

That reporting structure limits the reliability of standalone market-size estimates. A defensible financial assessment should separate:

1. Pharmaceutical-grade corn oil.
2. Food-grade corn oil used in non-drug products.
3. Corn oil used in dietary supplements.
4. Corn-oil derivatives, including fatty acids, glycerides, and surfactants.
5. Formulated lipid excipient systems that contain corn oil but are sold under a different product category.

Pharmaceutical demand is a small portion of total corn-oil consumption. The pharmaceutical segment has higher unit value than commodity food oil, but its volume is limited. Its economics depend more on qualification and consistency than on total global oil consumption.

What drives the financial trajectory of pharmaceutical-grade corn oil?

The financial trajectory is stable to moderately positive in nominal terms, with margins exposed to feedstock volatility.

Feedstock and commodity pricing

Corn oil is a coproduct of corn processing, particularly wet milling and ethanol production. Supply is influenced by:

• Corn crop yields
• Ethanol production
• Corn-processing capacity
• Energy prices
• Weather conditions
• Export demand
• Biofuel policy
• Competing demand for feed and industrial oil

Because corn oil is linked to agricultural markets, pharmaceutical-grade pricing can move even when pharmaceutical demand is unchanged. Refining, testing, packaging, inventory, and qualification costs create a premium over bulk industrial or food-grade oil.

Pharmaceutical qualification costs

Qualification creates customer retention. A drug manufacturer may avoid changing corn-oil suppliers because a source change can require:

• Supplier audits
• Comparative testing
• Stability studies
• Regulatory documentation
• Batch-to-batch equivalence work
• Manufacturing validation
• Potential regulatory notification or submission updates

These barriers do not constitute legal exclusivity, but they can support recurring sales and reduce short-term price competition.

Softgel and lipid-formulation demand

Softgel capsules remain an important demand channel. Demand is supported by oral medicines, vitamins, nutraceuticals, and consumer-health products. Pharmaceutical demand for lipid-based formulations also benefits from the development of poorly water-soluble compounds.

Corn oil competes in these applications with soybean oil, olive oil, sesame oil, medium-chain triglycerides, fractionated coconut oil, and synthetic lipid excipients. Selection is based on solubility, oxidation profile, sensory properties, compatibility, regulatory precedent, and cost.

Inflation and manufacturing costs

Pharmaceutical-grade suppliers face higher costs than commodity processors because they must maintain controlled facilities, validated cleaning, documentation systems, analytical laboratories, and quality release procedures. Cost inflation affects:

• Refining and filtration
• Nitrogen blanketing
• Antioxidant systems
• Packaging
• Warehousing
• Quality testing
• Freight
• Regulatory compliance

The ability to pass those costs through depends on contract structure and customer concentration.

How does corn oil compare with competing pharmaceutical lipid excipients?

Excipient	Relative strengths	Key disadvantages	Competitive position
Corn oil	Established, broadly available, familiar in softgels, moderate cost	Oxidation sensitivity, commodity exposure, variable composition	Cost-oriented conventional vehicle
Soybean oil	Extensive pharmaceutical precedent, common in emulsions	Allergen and source documentation, oxidation concerns	Strong conventional competitor
Medium-chain triglycerides	Good oxidation stability, predictable composition, useful in lipid formulations	Higher cost in some markets, different solubility behavior	Strong substitute in oral and nutrition products
Olive oil	Consumer familiarity, emollient properties	Higher cost, sensory and composition variation	Niche and premium positioning
Sesame oil	Established use in some injectable and oral products	Allergen concerns, oxidation and sourcing considerations	Route- and region-specific competitor
Mineral oil	High stability and low oxidation	Limited suitability for many drug-delivery applications	Restricted substitute
Synthetic glycerides	Defined composition and formulation performance	Higher price and more complex sourcing	Preferred for performance-driven formulations

Corn oil competes effectively when the formulation needs a conventional, lipophilic carrier and does not require advanced release or bioavailability enhancement. It is less competitive when the product requires tightly defined lipid composition, high oxidative stability, or specialized intestinal absorption behavior.

What formulation patents protect corn-oil products?

Corn oil itself is not generally protected by a pharmaceutical composition patent. It is a naturally derived mixture with long-established commercial use. Patent protection may cover a specific formulation containing corn oil, but the enforceable scope depends on the claims.

Potentially relevant patent categories include:

• A drug product containing a specified amount of corn oil
• A softgel formulation with defined active-to-oil ratios
• A self-emulsifying system containing corn oil and surfactants
• A parenteral emulsion with a defined droplet-size distribution
• A stabilized formulation with antioxidants
• A method of improving absorption using a corn-oil carrier
• A manufacturing process controlling oxidation or fill uniformity

Patent strength depends on whether the claims require corn oil specifically or permit a broad class of vegetable oils. A claim directed to "a lipid vehicle" may be easier to design around than a claim requiring a defined corn-oil composition and performance limitation.

Method-of-use patents

Method-of-use patents may cover administration of a particular active ingredient in a corn-oil formulation. Such patents can be relevant to branded drug products, but they do not establish exclusivity over pharmaceutical corn oil as an excipient.

Generic applicants may challenge method-of-use claims through a Paragraph IV certification or use a section viii statement where applicable, depending on the listing and the approved labeling. The risk is product-specific and cannot be inferred from the presence of corn oil alone.

What is the Orange Book status of corn oil?

Corn oil has no standalone Orange Book listing. The Orange Book lists approved drug products, patents, and exclusivity information associated with those products, not excipients as independent commercial assets. [3]

A finished drug containing corn oil may have Orange Book-listed patents covering:

• The active ingredient
• The dosage form
• The formulation
• A method of treatment
• A delivery system
• Manufacturing or stability characteristics

Those patents protect the drug product or its use. They do not confer exclusive rights to sell or supply corn oil for unrelated products.

Are there Paragraph IV challenges involving corn oil?

There is no general Paragraph IV challenge directed to corn oil as an excipient. Paragraph IV litigation concerns patents listed in connection with an approved drug product. A generic applicant could challenge a patent covering a finished formulation that contains corn oil, but the dispute would concern the drug product claims, not the underlying commodity excipient.

The commercial risk to a corn-oil supplier from generic entry is indirect. Generic entry can increase demand for qualified excipient supply, but it can also reduce branded-product volumes or shift purchasing to lower-cost suppliers.

What manufacturing and intellectual-property barriers affect supply?

The main barriers are operational rather than patent-based.

Manufacturing barriers

Suppliers must manage:

• Oxidation during refining and storage
• Trace contaminants from agricultural inputs
• Moisture and hydrolytic degradation
• Batch consistency
• Container compatibility
• Temperature control
• Microbial control for sensitive applications
• Documentation and change-control requirements

For injectable applications, requirements become substantially more demanding. A supplier may need dedicated controls, low bioburden processing, endotoxin management, and extensive stability data.

Intellectual-property barriers

IP may protect:

• Specialized refining processes
• Antioxidant combinations
• Encapsulation or dispersion systems
• Emulsion-processing methods
• Drug-specific formulations
• Packaging systems that reduce oxidation

These rights can support premium pricing in specialty applications, but they do not create broad exclusivity over corn oil.

Which companies compete in the corn-oil supply chain?

The supply chain includes agricultural processors, food-oil refiners, specialty excipient suppliers, and contract manufacturers. Relevant industry participants may include large corn processors and oil producers such as Archer Daniels Midland, Cargill, Ingredion, and other regional refiners. Pharmaceutical customers may purchase directly or through specialty distributors.

The critical distinction is between commodity availability and pharmaceutical qualification. A large producer may have abundant corn-oil capacity but limited pharmaceutical-grade sales. A specialty supplier may not own the agricultural feedstock but may add value through purification, packaging, testing, documentation, and customer support.

What generic launch risks exist for drugs containing corn oil?

Corn oil does not materially increase generic launch risk by itself. The principal risks are tied to the finished drug.

Risk category	Impact on generic entry
Active-ingredient patent	Can delay entry until expiry or settlement
Formulation patent	May require design-around or litigation
Method-of-use patent	May permit labeling or indication carve-outs
Bioequivalence	Lipid vehicles can affect absorption and variability
Stability	Oxidation and degradation may require additional data
Supplier qualification	Usually manageable but can affect launch timing
Manufacturing process	May create technical or validation challenges

For a generic softgel, the formulation vehicle may affect dissolution, drug release, bioavailability, and stability. A generic applicant may use corn oil, another vegetable oil, or a synthetic lipid if the alternative meets equivalence requirements.

What licensing deals and commercial agreements matter?

Licensing for corn oil itself is uncommon. Commercial arrangements usually take the form of:

• Multi-year supply agreements
• Dual-source qualification agreements
• Private-label manufacturing
• Distribution contracts
• Technical-quality agreements
• Minimum-volume commitments
• Price-adjustment mechanisms linked to commodity indices

The most important commercial asset is often an approved supplier position. Once a pharmaceutical customer qualifies a supplier, switching can require technical and regulatory work. This creates practical account stickiness without creating formal exclusivity.

What is the five-year financial outlook for pharmaceutical corn oil?

The base-case outlook is low-single-digit volume growth with potentially higher revenue growth during periods of commodity inflation. The market should remain resilient because corn oil is established, available, and familiar to formulation scientists.

Positive drivers

• Continued softgel production
• Growth in oral lipid formulations
• Expansion of pharmaceutical manufacturing in emerging markets
• Increased demand for qualified excipient supply
• Greater use of lipid vehicles for poorly soluble compounds
• Pharmaceutical outsourcing and contract manufacturing

Negative drivers

• Substitution by medium-chain triglycerides
• Increased use of synthetic and semisynthetic lipid excipients
• Oxidation-related product failures
• Agricultural price volatility
• Customer consolidation
• Pressure to use lower-cost food or supplement-grade alternatives
• Preference for more compositionally defined excipients

The strongest growth is likely to occur in specialty lipid systems rather than undifferentiated bulk corn oil. Suppliers that provide formulation support, oxidation-control systems, regulatory documentation, and reliable global distribution should capture better margins than suppliers competing only on oil price.

Key Takeaways

• Corn oil is an established pharmaceutical excipient used mainly as a vehicle, solvent, and lipid phase.
• The market is stable but lacks the high growth profile of advanced lipid and polymer excipients.
• No standalone Orange Book, exclusivity, or Paragraph IV framework applies to corn oil.
• Commercial defensibility comes from qualification, quality systems, supply reliability, and customer switching costs.
• Commodity corn prices, ethanol production, crop conditions, and refining capacity drive input costs.
• Medium-chain triglycerides and synthetic glycerides are the main performance-oriented substitutes.
• Formulation patents may cover drug products containing corn oil, but they do not generally protect corn oil itself.
• Pharmaceutical-grade supply should command a premium over food-grade material because of testing, documentation, and change-control requirements.
• The most attractive financial opportunities are in qualified, high-purity, oxidation-controlled, and formulation-supported products.
• The base-case market trajectory is steady volume growth with margin volatility tied to agricultural and processing costs.

FAQs

Is corn oil an FDA-approved excipient?

Corn oil is not approved independently as a drug product. Its acceptability is assessed within each finished drug application, with prior-use information available through FDA excipient resources.

Can corn oil be used in injectable medicines?

Potentially, but injectable use requires much stricter controls than oral use, including sterility-related controls, endotoxin management, particulate limits, oxidative stability, and route-specific safety justification.

Is pharmaceutical corn oil different from food-grade corn oil?

Yes. Pharmaceutical-grade material is produced and documented to meet drug-manufacturing requirements. Food-grade material may not have the testing, traceability, change control, or regulatory documentation required for a pharmaceutical product.

Does corn oil improve drug bioavailability?

It can improve the solubilization or absorption of some lipophilic drugs, but the effect depends on the active ingredient, dose, formulation composition, digestion behavior, and dosage form.

Which excipient is a stronger substitute for corn oil?

Medium-chain triglycerides are often the strongest functional substitute where oxidation stability and predictable lipid behavior are priorities. Soybean oil is a close conventional substitute in many established formulations.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2018). Reflection paper on the pharmaceutical development of medicines for use in the older population. https://www.ema.europa.eu/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. Archer-Daniels-Midland Company. (2024). Annual report. https://www.adm.com/investors/financial-information/annual-reports/